Sage Therapeutics Inc is a biopharmaceutical company focused on innovating brain health medicines. It has developed ZULRESSO, a treatment for postpartum depression, and is working on other promising drugs like ZURZUVAE for the same condition, SAGE-324 for essential tremors, and SAGE-718 aimed at various neurological disorders including depression and Alzheimer's disease. The company collaborates with global partners like Shionogi & Co. and Biogen MA Inc. to expand its reach. Founded in 2010 and based in Cambridge, Massachusetts, Sage Therapeutics is committed to addressing unmet needs in brain health.